Replimune Group: Q3 Earnings Insights
Replimune Group (NASDAQ:REPL) reported its Q3 earnings results on Thursday, February 3, 2022 at 08:00 AM.
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson’s Program
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Piper Sandler Initiates Coverage On Replimune Group with Overweight Rating, Announces Price Target of $52
Piper Sandler analyst Do Kim initiates coverage on Replimune Group (NASDAQ:REPL) with a Overweight rating and announces Price Target of $52.
Replimune Group Q2 EPS $(0.56) Down From $(0.46) YoY
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.56) per share. This is a 21.74 percent decrease over losses of $(0.46) per share from the same period last year.
10 Biggest Price Target Changes For Monday
Telsey Advisory Group boosted the price target for Burlington Stores, Inc. (NYSE: BURL) from $380 to $400. Burlington fell 0.4% to close at $347.52 on Friday.
SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $49
SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and lowers the price target from $55 to $49.
SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $55
SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and lowers the price target from $56 to $55.
Replimune Group Q1 EPS $(0.53) Down From $(0.44) YoY
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.53) per share. This is a 20.45 percent decrease over losses of $(0.44) per share from the same period last year.